Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-EN | Version v7-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-04-08 | 2025-04-07 |
| Drug Identification Number | 02537214 | 02537214 |
| Brand name | BEYFORTUS | BEYFORTUS |
| Common or Proper name | Beyfortus | Beyfortus |
| Company Name | SANOFI PASTEUR LIMITED | SANOFI PASTEUR LIMITED |
| Ingredients | NIRSEVIMAB | NIRSEVIMAB |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR | INTRAMUSCULAR |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 100 mg single-use, pre-filled syringe | 100 mg single-use, pre-filled syringe |
| ATC code | J06BD | J06BD |
| ATC description | ||
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2024-12-20 | 2024-12-20 |
| Actual start date | 2024-12-19 | 2024-12-19 |
| Estimated end date | 2025-03-30 | 2025-03-30 |
| Actual end date | 2025-04-07 | 2025-04-07 |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Sanofi is proactively securing additional doses from our global supply to quickly respond to an increase in demand, following inquiries for more doses to address a predicted surge in provincial uptake as the RSV season is projected to peak in January. The additional volumes are pre-emptive in nature and beyond the provincial contractual commitments. | Sanofi is proactively securing additional doses from our global supply to quickly respond to an increase in demand, following inquiries for more doses to address a predicted surge in provincial uptake as the RSV season is projected to peak in January. The additional volumes are pre-emptive in nature and beyond the provincial contractual commitments. |
| Health Canada comments |